SANES

10.154

-0.84%↓

BBVA

18.865

-0.68%↓

BNP

86.07

-2.79%↓

CABK

11.02

-0.32%↓

INGA

25.18

-1.45%↓

SANES

10.154

-0.84%↓

BBVA

18.865

-0.68%↓

BNP

86.07

-2.79%↓

CABK

11.02

-0.32%↓

INGA

25.18

-1.45%↓

SANES

10.154

-0.84%↓

BBVA

18.865

-0.68%↓

BNP

86.07

-2.79%↓

CABK

11.02

-0.32%↓

INGA

25.18

-1.45%↓

SANES

10.154

-0.84%↓

BBVA

18.865

-0.68%↓

BNP

86.07

-2.79%↓

CABK

11.02

-0.32%↓

INGA

25.18

-1.45%↓

SANES

10.154

-0.84%↓

BBVA

18.865

-0.68%↓

BNP

86.07

-2.79%↓

CABK

11.02

-0.32%↓

INGA

25.18

-1.45%↓

Accueil・Liste d'Actions・Bayer AG

Bayer AG

Fermé

SecteurFinance

38.51 2.39

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

37.61

Max

39.19

Chiffres clés
By Trading Economics
Revenu	-2.8B -3.8B
Ventes	1.8B 11B
BPA	-3.82
Rendement du dividende	0.3
Marge bénéficiaire	-32.847
Employés	87,280
EBITDA	1.4B 2B

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+27.36% upside

Dividendes
By Dow Jones
Rendement du dividende Moyenne du Secteur	0.30% 4.52%
Prochains Résultats	4 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-3.5B 36B
Ouverture précédente	36.12
Clôture précédente	38.51

Sentiment de l'Actualité

By Acuity

30%

70%

62 / 438 Classement par Finance

Score Technique

By Trading Central

Confiance

Bearish Evidence

22.99 / 23.88 Support & Résistance

Bayer AG Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

12 mai 2026, 11:24 UTC

Résultats

Principaux Mouvements du Marché

Bayer Shares Climb After Earnings Beat Expectations

12 mai 2026, 06:10 UTC

Résultats

Bayer Net Profit Surges Driven by Growth in Agricultural Division

6 mai 2026, 10:51 UTC

Acquisitions, Fusions, Rachats

Bayer to Buy Eye-Drug Developer Perfuse Therapeutics for Up to $2.45 Billion -- Update

6 mai 2026, 07:01 UTC

Acquisitions, Fusions, Rachats

Bayer to Buy Eye-Drug Developer Perfuse Therapeutics for Up to $2.45 Billion

12 mai 2026, 12:05 UTC

Actions en Tendance

Stocks to Watch: GameStop, Venture Global, Wendy's, Hims & Hers -- WSJ

12 mai 2026, 10:51 UTC

Actions en Tendance

Stocks to Watch: GameStop, Venture Global, Hims & Hers, GoPro -- WSJ

12 mai 2026, 09:08 UTC

Actions en Tendance

Stocks to Watch: Venture Global, Hims & Hers, GoPro -- WSJ

12 mai 2026, 05:38 UTC

Résultats

Bayer Backs 2026 Outlook Adjusted for Currency

12 mai 2026, 05:36 UTC

Résultats

Bayer 1Q Consumer Health Sales Grew 5.3%, Adjusted for Currency, Portfolio Changes

12 mai 2026, 05:36 UTC

Résultats

Bayer 1Q Pharma Sales Fell 0.5%, Adjusted for Currency, Portfolio Changes

12 mai 2026, 05:36 UTC

Résultats

Bayer 1Q Crop Science Sales Grew 6.8%, Adjusted for Currency, Portfolio Changes

12 mai 2026, 05:35 UTC

Résultats

Bayer 1Q Adj EPS EUR2.71

12 mai 2026, 05:34 UTC

Résultats

Analysts Saw Bayer 1Q Net Profit From Continuing Operations at EUR1.60B

12 mai 2026, 05:34 UTC

Résultats

Analysts Saw Bayer 1Q Ebitda Before Special Items at EUR3.93B

12 mai 2026, 05:34 UTC

Résultats

Analysts Saw Bayer 1Q Sales at EUR13.42B

12 mai 2026, 05:34 UTC

Résultats

Bayer 1Q Sales Grew 4.1% When Adjusted for Currency, Portfolio Changes

12 mai 2026, 05:33 UTC

Résultats

Bayer 1Q EBIT EUR3.53B

12 mai 2026, 05:32 UTC

Résultats

Bayer 1Q Ebitda Before Special Items EUR4.45B

12 mai 2026, 05:32 UTC

Résultats

Bayer 1Q Net Pft EUR2.76B

12 mai 2026, 05:31 UTC

Résultats

Bayer 1Q Sales EUR13.405B

12 mai 2026, 05:31 UTC

Résultats

Bayer Backs 2026 View

6 mai 2026, 06:34 UTC

Acquisitions, Fusions, Rachats

Bayer: Perfuse's Lead Program Is Treatment for Glaucoma and Diabetic Retinopathy

6 mai 2026, 06:33 UTC

Acquisitions, Fusions, Rachats

Bayer: Acquisition Aims to Complement Ophthalmology Pipeline

6 mai 2026, 06:33 UTC

Acquisitions, Fusions, Rachats

Bayer: Additional Payments Subject to Development, Regulatory, and Commercial Milestones

6 mai 2026, 06:32 UTC

Acquisitions, Fusions, Rachats

Bayer to Pay $300M Upfront

6 mai 2026, 06:32 UTC

Acquisitions, Fusions, Rachats

Bayer to Buy Perfuse Therapeutics for Up to $2.45B

6 mai 2026, 06:31 UTC

Acquisitions, Fusions, Rachats

Bayer to Buy Perfuse Therapeutics

6 mai 2026, 06:30 UTC

Acquisitions, Fusions, Rachats

Bayer To Acquire Perfuse Therapeutics To Complement Ophthalmology Pipeline >BAYN.XE

8 avr. 2026, 14:41 UTC

Résultats

Buy Johnson & Johnson Stock Ahead of Earnings, Analyst Says. The Gains Can Continue. -- Barrons.com

1 avr. 2026, 14:24 UTC

Market Talk

Bayer Pharma Head Touts Healthiest Pipeline in Company's History -- Market Talk

Comparaison

Variation de prix

Bayer AG prévision

Objectif de Prix

By TipRanks

27.36% hausse

Prévisions sur 12 Mois

Moyen 48.18 EUR 27.36%

Haut 56 EUR

Bas 25 EUR

Basé sur 12 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

12 ratings

Achat

Maintien

Vente

Basé sur 12 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

22.99 / 23.88Support & Résistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Sentiment

By Acuity

62 / 438Classement par Finance

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Bayer AG

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment provides breeding, propagation, and production/processing of seeds, including seed dressing. It has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases; and collaboration and license agreement with Cytokinetics for the development and commercialization of aficamten. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company was founded in 1863 and is headquartered in Leverkusen, Germany.